Weiss Ratings Reiterates Sell (D-) Rating for Dominari (NASDAQ:DOMH)

Key Points

• Weiss Ratings has maintained a "sell (D-)" rating for Dominari (NASDAQ:DOMH), despite a recent upgrade from Wall Street Zen which rated it a "buy".
• Dominari's stock has decreased to $6.47 per share, with a notable 1-year price range of $0.83 to $13.58.
• The company reported a loss of ($1.02) EPS for its last quarterly earnings, along with a negative net margin of 36.01%.

Dominari (NASDAQ:DOMH - Get Free Report)'s stock had its "sell (d-)" rating reiterated by Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen upgraded Dominari from a "sell" rating to a "buy" rating in a research report on Saturday, August 16th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of "Sell".

Dominari Stock Down 0.9%

Shares of DOMH traded down $0.06 during mid-day trading on Wednesday, hitting $6.47. 433,447 shares of the company traded hands, compared to its average volume of 365,748. Dominari has a 1-year low of $0.83 and a 1-year high of $13.58. The company has a market capitalization of $100.54 million, a PE ratio of -2.73 and a beta of 0.75. The business has a 50 day moving average of $6.27 and a 200 day moving average of $5.37.

Dominari (NASDAQ:DOMH - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($1.02) earnings per share (EPS) for the quarter. Dominari had a negative net margin of 36.01% and a negative return on equity of 94.32%. The company had revenue of $34.10 million for the quarter.

Institutional Investors Weigh In On Dominari

Hedge funds have recently bought and sold shares of the stock. Magnus Financial Group LLC purchased a new position in shares of Dominari during the 2nd quarter valued at approximately $136,000. Jane Street Group LLC acquired a new position in Dominari in the 2nd quarter valued at $158,000. Geode Capital Management LLC increased its stake in shares of Dominari by 2.9% in the 2nd quarter. Geode Capital Management LLC now owns 66,283 shares of the company's stock worth $361,000 after acquiring an additional 1,866 shares during the last quarter. PFG Investments LLC acquired a new stake in shares of Dominari in the 1st quarter worth $566,000. Finally, Connective Capital Management LLC purchased a new position in shares of Dominari during the 2nd quarter worth $1,446,000. Hedge funds and other institutional investors own 42.48% of the company's stock.

About Dominari

Dominari Holdings Inc, a biotechnology company, focuses on developing small-molecule anticancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.